The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of ...

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend ...

The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...

The U.S. Food and Drug Administration approved on Friday labeling changes for the blood cancer therapy of Johnson & Johnson ...

The U.S. Food and Drug Administration (FDA) has updated the safety labeling for Carvykti, the multiple myeloma therapy ...

The US Food and Drug Administration (FDA) on Friday revealed it has received reports of immune effector cell-associated ...

Legend Biotech ( ($LEGN) ) just unveiled an announcement. On October 14, 2025, Legend Biotech announced that its product CARVYKTI® achieved ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.